by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The organization would become more difficult to operate should Novo Nordisk reach its ambition of continuing on its current growth track, which has catapulted the company all the way to the upper echelons as one of the world’s biggest pharmaceutical companies.
”A lot of people probably don’t think about it in everyday life, but Novo Nordisk has actually become one of the world’s biggest pharmaceutical firms. We’re continuing to grow, and if we succeed with our strategy, we will have even more therapeutic areas in a few years,” says Helge Lund, chair of the board at Novo Nordisk, adding:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Cell Culture Scientist/Senior Scientist 
Chemist for Incoming Materials in QC Department 
Director of Toxicology 
System Sales Development Consultant - Investment Projects, Merck Millipore 
2 Sales Representatives and Product Specialists 
Client Talent Acquisition Specialist 
Communications Consultant 
Clinical Project Manager 
Procurement Process Excellence Specialist 
Process Manager 
Director Global Engineering 
(Senior) Drug Substance Specialist 
Nordic Medical Affairs Manager 
Key Account Manager, Europe and Asia